Tucatinib in Patients With CRC: Data From MOUNTAINEER-01
In the Phase 2 MOUNTAINEER-01 study of patients with HER2-positive metastatic colorectal cancer who were chemo-refractory, the combination of tucatinib and trastuzumab showed an impressive response rate and disease control rate, and median duration of response up to 12 months; Dr. Ahn notes these results compare favorably to prior studies of dual HER2 inhibition, with MOUNTAINEER-01 showing higher response rates.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
